GLP-1 RAs have robust cardiorenal benefits but require awareness of GI effects, potential pancreatitis risk, thyroid concerns, and emerging safety signals for evidence-based risk management.
Benefits > risksDespite up to 80% GI effects, GLP-1 drugs' cardiovascular and renal benefits strongly favor their use with appropriate management
What the researchers found
GLP-1 RAs: GI effects (up to 80%), pancreatitis (monitoring needed), thyroid concerns (animal > human data), established CV/renal benefits, emerging safety signals requiring surveillance.
Why it matters
Millions take GLP-1 drugs. Comprehensive safety knowledge enables better prescribing and patient counseling.
How the study worked
Comprehensive safety review of GLP-1 RA adverse effects as glucose-lowering agents.
What this study cannot tell us
Review. Some emerging signals need longer-term data.
How to read the evidence
Comprehensive review of clinical trial and post-marketing safety data.
When this study was published
Published in 2025.
The bigger picture
The GLP-1 safety profile is well-characterized — benefits strongly outweigh risks for most patients, but individualized management is key.
Questions still open
- Should dose titration protocols be standardized to minimize GI effects?
- Is the pancreatitis risk real or overstated?
- Will emerging safety signals prove clinically significant?
Common questions
What are the main side effects of GLP-1 drugs?
Are GLP-1 drugs safe overall?
Read the original research
The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.
The Journal of clinical investigation, 136(4)
Citation
Jalleh, Ryan J; Talley, Nicholas J; Horowitz, Michael; Nauck, Michael A. (2026). The science of safety: adverse effects of GLP-1 receptor agonists as glucose-lowering and obesity medications.. The Journal of clinical investigation, 136(4). https://doi.org/10.1172/JCI194740